SCHEMBL4214031

SCHEMBL4214031

COc1ccc(S(=O)(=O)Nc2ccc(OC)c3c2OC[C@H](N(C)C)C3)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 8/20 0.46
KEAP1 Q14145 2/20 0.44
SQSTM1 Q13501 1/20 0.44
NFE2L2 Q16236 1/20 0.44
ALDH1A1 P00352 5/20 0.44
TSHR P16473 3/20 0.44
KMT2A Q03164 3/20 0.44
HTT P42858 2/20 0.44
NPSR1 Q6W5P4 1/20 0.44
JAK2 O60674 1/20 0.44
HSD11B1 P28845 1/20 0.43
HSD17B2 P37059 1/20 0.43
POLB P06746 1/20 0.43
CYP2C9 P11712 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
HTR6 P50406 1/20 0.43
QRFPR Q96P65 1/20 0.43
FFAR4 Q5NUL3 1/20 0.42
MAPT P10636 3/20 0.41
MEN1 O00255 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4207244 0.92 HTR6 (0.43) LMNAKEAP1NFE2L2ALDH1A1KMT2A
SCHEMBL4199467 0.92 HTR6 (0.43) LMNAKEAP1NFE2L2ALDH1A1TSHR
SCHEMBL4210204 0.91 GHSR (0.47) LMNAKEAP1SQSTM1NFE2L2CYP2C9
SCHEMBL4207490 0.91 HTR6 (0.51) LMNAALDH1A1KMT2AHTTNPSR1
SCHEMBL4200898 0.91 ALDH1A1 (0.45) LMNAKEAP1NFE2L2ALDH1A1HTR6
SCHEMBL4205717 0.91 GHSR (0.43) LMNAKEAP1NFE2L2ALDH1A1TSHR
SCHEMBL4209142 0.91 HTR6 (0.42) LMNAKEAP1NFE2L2ALDH1A1TSHR
SCHEMBL4209213 0.91 HTR6 (0.47) KEAP1NFE2L2ALDH1A1SMN1; SMN2HTR6
SCHEMBL4207457 0.90 FFAR4 (0.40) LMNAALDH1A1TSHRKMT2AHTT
SCHEMBL4205765 0.90 KEAP1 (0.50) LMNAKEAP1NFE2L2ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090030038-A1 Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor ASTRAZENECA AB (SE) 2009-01-29 US claimed
EP-1888517-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR AstraZeneca AB (SE) 2008-02-20 EP claimed
WO-2006126939-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR ASTRAZENECA AB (SE) 2006-11-30 WO claimed
US-20090030038-A1 Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor ASTRAZENECA AB (SE) 2009-01-29 US disclosed
EP-1888517-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR AstraZeneca AB (SE) 2008-02-20 EP disclosed
WO-2006126939-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR ASTRAZENECA AB (SE) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030038-A1 Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor HTR6, HTR1A, HTR1D LMNA 1549/4885KEAP1 4543/4885SQSTM1 3481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.